PURPOSE: To evaluate survival and clinical outcome for patients with a large uveal melanoma treated by either enucleation or proton beam radiotherapy (PBRT). PROCEDURES: This retrospective non-randomized study evaluated 132 consecutive patients with T3 and T4 choroidal melanoma classified according to TNM stage grouping. RESULTS: Cumulative all-cause mortality, melanoma-related mortality and metastasis-free survival were not statistically different between the two groups (log-rank test, p = 0.56, p = 0.99 and p = 0.25, respectively). Eye retention of the tumours treated with PBRT at 5 years was 74% (SD 6.2%). In these patients at diagnosis, 73% of eyes had a best-corrected visual acuity (BCVA) of 0.1 or better. After 12 and 60 months, BCVA of 0.1 or better was observed in 47.5 and 32%, respectively. CONCLUSION AND MESSAGE: Although enucleation is the most common primary treatment for large uveal melanomas, PBRT is an eye-preserving option that may be considered for some patients.
PURPOSE: To evaluate survival and clinical outcome for patients with a large uveal melanoma treated by either enucleation or proton beam radiotherapy (PBRT). PROCEDURES: This retrospective non-randomized study evaluated 132 consecutive patients with T3 and T4 choroidal melanoma classified according to TNM stage grouping. RESULTS: Cumulative all-cause mortality, melanoma-related mortality and metastasis-free survival were not statistically different between the two groups (log-rank test, p = 0.56, p = 0.99 and p = 0.25, respectively). Eye retention of the tumours treated with PBRT at 5 years was 74% (SD 6.2%). In these patients at diagnosis, 73% of eyes had a best-corrected visual acuity (BCVA) of 0.1 or better. After 12 and 60 months, BCVA of 0.1 or better was observed in 47.5 and 32%, respectively. CONCLUSION AND MESSAGE: Although enucleation is the most common primary treatment for large uveal melanomas, PBRT is an eye-preserving option that may be considered for some patients.
Authors: Tara A McCannel; Mitchell Kamrava; Jeffrey Demanes; James Lamb; John D Bartlett; Robert Almanzor; Melissa Chun; Colin A McCannel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-09-16 Impact factor: 3.117
Authors: Thanos D Papakostas; Anne Marie Lane; Margaux Morrison; Evangelos S Gragoudas; Ivana K Kim Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Benjamin A King; Caroline Awh; Brad T Gao; Jiajing Wang; Mehmet Kocak; Vanessa M Morales-Tirado; Matthew T Ballo; Matthew W Wilson Journal: Ocul Oncol Pathol Date: 2019-01-10
Authors: Youn Joo Choi; Tae Wan Kim; Suzy Kim; Hokyung Choung; Min Joung Lee; Namju Kim; Sang In Khwarg; Young Suk Yu Journal: J Korean Med Sci Date: 2018-04-16 Impact factor: 2.153
Authors: Marina Marinkovic; Lennart J Pors; Vincent van den Berg; Femke P Peters; Ann Schalenbourg; Leonidas Zografos; Alessia Pica; Jan Hrbacek; Sjoerd G Van Duinen; T H Khanh Vu; Jaco C Bleeker; Coen R N Rasch; Martine J Jager; Gregorius P M Luyten; Nanda Horeweg Journal: Cancers (Basel) Date: 2021-12-13 Impact factor: 6.639